par Stamatopoulos, Basile 
;Smith, Thomas Bates;Crompot, Emerence ;Pieters, Karlien ;Clifford, Ruth;Mraz, Marek;Robbe, Pauline;Burns, Adam;Timbs, Adele;Bruce, D.W;Hillmen, Peter;Meuleman, Nathalie ;Mineur, Philippe;Firescu, R;Maerevoet, Marie ;De Wilde, Virginie ;Efira, André ;Philippé, Jan;Verhasselt, Bruno;Offner, Firtz;Sims, David;Heger, Andreas;Dreau, Hélène;Schuh, Anna
Référence Clinical cancer research
Publication Publié, 2018-06
;Smith, Thomas Bates;Crompot, Emerence ;Pieters, Karlien ;Clifford, Ruth;Mraz, Marek;Robbe, Pauline;Burns, Adam;Timbs, Adele;Bruce, D.W;Hillmen, Peter;Meuleman, Nathalie ;Mineur, Philippe;Firescu, R;Maerevoet, Marie ;De Wilde, Virginie ;Efira, André ;Philippé, Jan;Verhasselt, Bruno;Offner, Firtz;Sims, David;Heger, Andreas;Dreau, Hélène;Schuh, AnnaRéférence Clinical cancer research
Publication Publié, 2018-06
Article révisé par les pairs
| Résumé : | Unmutated (UM) immunoglobulin heavy chain variable region (IgHV) status or IgHV3-21 gene usage is associated with poor prognosis in chronic lymphocytic leukemia (CLL) patients. Interestingly, IgHV3-21 is often co-expressed with light chain IgLV3-21, which is potentially able to trigger cell-autonomous BCR-mediated signaling. However, this light chain has never been characterized independently of the heavy chain IgHV3-21. |
